Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EBIT (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed EBIT for 3 consecutive years, with -$26.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, EBIT fell 12.5% year-over-year to -$26.1 million, compared with a TTM value of -$126.9 million through Dec 2021, down 82.37%, and an annual FY2024 reading of -$78.8 million, up 8.88% over the prior year.
  • EBIT was -$26.1 million for Q4 2021 at Black Diamond Therapeutics, up from -$35.4 million in the prior quarter.
  • Across five years, EBIT topped out at -$3.8 million in Q1 2019 and bottomed at -$35.4 million in Q3 2021.
  • Average EBIT over 3 years is -$18.8 million, with a median of -$16.8 million recorded in 2020.
  • The sharpest move saw EBIT crashed 235.3% in 2020, then fell 12.5% in 2021.
  • Year by year, EBIT stood at -$10.3 million in 2019, then crashed by 124.12% to -$23.2 million in 2020, then fell by 12.5% to -$26.1 million in 2021.
  • Business Quant data shows EBIT for BDTX at -$26.1 million in Q4 2021, -$35.4 million in Q3 2021, and -$34.7 million in Q2 2021.